propafenone has been researched along with Tachycardia, Ventricular in 43 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 7.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 6.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 5.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Spontaneous monomorphic and polymorphic ventricular tachycardias (VT) were observed during monitoring." | 5.33 | Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report. ( Dinckal, MH; Karaca, M, 2006) |
| "Propafenone is an antiarrhythmic drug used in the treatment of life-threatening ventricular tachyarrhythmias." | 5.30 | Propafenone-induced drug fever in the absence of agranulocytosis. ( Gerling, BR; Greenberg, ML; Holzberger, PT; O'Rourke, DJ; Palac, RT, 1997) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 5.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| " In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, randomized trial, was initiated to compare metoprolol, amiodarone, propafenone, and ICD implantation in patients surviving sudden cardiac death due to documented ventricular tachycardia and/or ventricular fibrillation." | 5.07 | Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators. ( Cappato, R; Kuck, KH; Rüppel, R; Schneider, MA; Siebels, J, 1993) |
| "Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function." | 3.85 | Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017) |
| "Ventricular arrhythmia (VA) can occur during propafenone therapy in atrial fibrillation (AF) patients with structurally normal heart." | 3.81 | Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. ( Chang, SL; Chang, Y; Chao, TF; Chen, SA; Chen, YY; Chien, KL; Chiou, CW; Chong, E; Chung, FP; Hu, YF; Liao, JN; Lin, CY; Lin, YJ; Lo, LW; Tuan, TC, 2015) |
| "The electrophysiological effects of combination therapy of mexiletine and propafenone were assessed using standard 12-lead electrocardiogram (standard ECG), signal-averaged ECG (SAECG), and ambulatory ECG in 31 patients with ventricular arrhythmias." | 3.68 | Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy. ( Haruna, M; Kato, H; Lee, S; Machii, T; Nonokawa, M; Takanaka, C; Yabe, S, 1992) |
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| " After a period of placebo administration, all patients underwent three consecutive periods during which they received Pr IR at the dosage of 150 mg x 3, Pr SR at the dosage of 225 mg x 2, Pr SR at the dosage of 325 mg x 2." | 2.69 | [Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms]. ( Massari, F; Mastropasqua, F; Pitzalis, MV; Rizzon, P; Totaro, P, 1998) |
| "Previous bradyarrhythmias or sick sinus syndrome (SSS), and concomitant use of antiarrhythmic drugs were exclusion criteria." | 2.68 | Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? ( Alfieri, G; Barone, P; Bernasconi, G; Bonini, W; Botto, GL; Broffoni, T; Ferrari, G; Lombardi, R; Molteni, S, 1996) |
| " The dosage from 50 to 100 mg/day made no difference." | 2.68 | Preliminary study of the effects of metoprolol and propafenone on ventricular arrhythmia with positive ventricular late potential. ( Duan, Y; Gao, E; Li, H; Yang, C; Zhou, Y, 1997) |
| "Overall efficacy of ventricular tachycardia pace termination was 69% and the time required to stop ventricular tachycardia was 14." | 2.67 | Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia. ( Green, MS; Kantoch, MJ; Tang, AS, 1993) |
| "In 1987, the Cardiac Arrest Study Hamburg (CASH), a prospective, multicenter, randomized controlled study, was started in survivors of sudden cardiac death resulting from documented ventricular tachyarrhythmias." | 2.67 | Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). ( Kuck, KH; Siebels, J, 1994) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "Procainamide is effective for stable ventricular tachycardia, and amiodarone is effective in the treatment of shock-refractory ventricular fibrillation." | 2.41 | Intravenous antiarrhythmic agents. ( Dorian, P; Pinter, A, 2001) |
| "No sustained ventricular tachycardia, ventricular fibrillation, sudden cardiac death, or cardiovascular mortality were observed." | 1.72 | Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation. ( Aksu, T; Aras, D; Cay, S; Kara, M; Ozcan, F; Ozeke, O; Topaloglu, S, 2022) |
| "Propafenone is a class 1C antiarrhythmic drug used in the second-line management of supraventricular and ventricular arrhythmias and, when unintentionally ingested, can lead to severe and life-threatening poisoning." | 1.51 | Ventricular Tachycardia Induced by Propafenone Intoxication in a Pediatric Patient. ( Di Mita, O; DʼAnna, C; Marzuillo, P; Pappacoda, S; Ponticiello, E; Rosa, M; Tipo, V, 2019) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare but potentially lethal inherited arrhythmia syndrome induced by adrenergic stress." | 1.48 | A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. ( Duan, H; Hua, Y; Li, Y; Lu, Y; Qiao, L; Wang, C; Yan, S; Zhou, K, 2018) |
| "Catecholaminergic polymorphic ventricular tachycardia (CPVT) is caused by mutations in the cardiac ryanodine receptor (RyR2) or calsequestrin (Casq2) and can be difficult to treat." | 1.37 | Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. ( Faggioni, M; Hasdemir, C; Hwang, HS; Knollmann, BC; Laver, D; Mehra, D; Turhan, K; Yin, H, 2011) |
| "Propafenone was stereoselective, with R-propafenone suppressing waves more potently than S-propafenone (IC(50): R-propafenone 2 ± 0." | 1.37 | Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. ( Galimberti, ES; Knollmann, BC, 2011) |
| "Electrocardiography (ECG) showed ventricular tachycardia." | 1.35 | A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation. ( Eroğlu, S; Müderrisoğlu, H; Ozbiçer, S; Ozin, B, 2009) |
| "Spontaneous monomorphic and polymorphic ventricular tachycardias (VT) were observed during monitoring." | 1.33 | Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report. ( Dinckal, MH; Karaca, M, 2006) |
| "Propafenone is an antiarrhythmic drug used in the treatment of life-threatening ventricular tachyarrhythmias." | 1.30 | Propafenone-induced drug fever in the absence of agranulocytosis. ( Gerling, BR; Greenberg, ML; Holzberger, PT; O'Rourke, DJ; Palac, RT, 1997) |
| " Dosage and serum levels of propafenone did not differ whether the patients were treated successfully or not." | 1.29 | Clinical experience with propafenone for cardiac arrhythmias in the young. ( Bourgeous, M; Heusch, A; Kramer, HH; Krogmann, ON; Rammos, S, 1994) |
| "Propafenone is an effective drug for the acute conversion of spontaneous monomorphic sustained ventricular tachycardia, especially in patients without organic heart disease." | 1.29 | [The efficacy and safety of intravenous propafenone in the acute treatment of spontaneous sustained ventricular tachycardia]. ( Madrid, AH; Marín-Huerta, E; Mestre, JL; Moro, C; Novo, L, 1994) |
| "Propafenone is a class Ic anti-arrhythmic agent with mild beta-blocking properties which has recently become available in South Africa." | 1.29 | Normal left ventricular function does not protect against propafenone-induced incessant ventricular tachycardia. ( Lawrenson, JB; Millar, RN; Milne, DA, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (58.14) | 18.2507 |
| 2000's | 7 (16.28) | 29.6817 |
| 2010's | 9 (20.93) | 24.3611 |
| 2020's | 2 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| Cay, S | 1 |
| Kara, M | 1 |
| Ozcan, F | 1 |
| Ozeke, O | 1 |
| Aksu, T | 1 |
| Aras, D | 1 |
| Topaloglu, S | 1 |
| Basza, M | 1 |
| Maciejewski, C | 1 |
| Bojanowicz, W | 1 |
| Balsam, P | 1 |
| Grabowski, M | 1 |
| Mitkowski, P | 1 |
| Kempa, M | 1 |
| Kowalski, O | 1 |
| Kalarus, Z | 1 |
| Jaguszewski, M | 1 |
| Lubiński, A | 1 |
| Daniłowicz-Szymanowicz, L | 1 |
| Szumowski, Ł | 1 |
| Sterliński, M | 1 |
| Kołtowski, Ł | 1 |
| Bergonti, M | 1 |
| Assanelli, E | 1 |
| Agostoni, P | 1 |
| Rosa, M | 1 |
| Pappacoda, S | 1 |
| DʼAnna, C | 1 |
| Di Mita, O | 1 |
| Ponticiello, E | 1 |
| Marzuillo, P | 1 |
| Tipo, V | 1 |
| Duan, H | 1 |
| Lu, Y | 1 |
| Yan, S | 1 |
| Qiao, L | 1 |
| Hua, Y | 1 |
| Li, Y | 1 |
| Zhou, K | 1 |
| Wang, C | 1 |
| Lin, CY | 1 |
| Lin, YJ | 1 |
| Lo, LW | 1 |
| Chen, YY | 1 |
| Chong, E | 1 |
| Chang, SL | 1 |
| Chung, FP | 1 |
| Chao, TF | 1 |
| Hu, YF | 1 |
| Tuan, TC | 1 |
| Liao, JN | 1 |
| Chang, Y | 1 |
| Chien, KL | 1 |
| Chiou, CW | 1 |
| Chen, SA | 1 |
| Li, X | 1 |
| Zhang, Y | 2 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Ge, H | 1 |
| Gilewski, W | 1 |
| Bednarska, D | 1 |
| Sinkiewicz, W | 1 |
| Eroğlu, S | 1 |
| Ozin, B | 1 |
| Ozbiçer, S | 1 |
| Müderrisoğlu, H | 1 |
| Pino, R | 1 |
| Sciortino, G | 1 |
| Polizzi, G | 1 |
| Hwang, HS | 1 |
| Hasdemir, C | 2 |
| Laver, D | 1 |
| Mehra, D | 1 |
| Turhan, K | 1 |
| Faggioni, M | 1 |
| Yin, H | 1 |
| Knollmann, BC | 2 |
| Galimberti, ES | 1 |
| Musayev, O | 1 |
| Kehribar, DY | 1 |
| Kartal, Y | 1 |
| Can, LH | 1 |
| Büyükavci, M | 1 |
| Olgun, H | 1 |
| Kertmen, B | 1 |
| Tan, H | 1 |
| Ceviz, N | 1 |
| Karaca, M | 1 |
| Dinckal, MH | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
| Heusch, A | 1 |
| Kramer, HH | 1 |
| Krogmann, ON | 1 |
| Rammos, S | 1 |
| Bourgeous, M | 1 |
| Siebels, J | 4 |
| Cappato, R | 2 |
| Rüppel, R | 2 |
| Schneider, MA | 2 |
| Kuck, KH | 4 |
| Kantoch, MJ | 1 |
| Green, MS | 1 |
| Tang, AS | 1 |
| Mestre, JL | 1 |
| Moro, C | 1 |
| Madrid, AH | 1 |
| Novo, L | 1 |
| Marín-Huerta, E | 1 |
| Stark, G | 1 |
| Dhein, S | 1 |
| Bachernegg, M | 1 |
| Ziskoven, U | 1 |
| Zhao, Y | 1 |
| Klaus, W | 1 |
| Kickenweiz, E | 1 |
| Decrinis, M | 1 |
| Tritthart, HA | 1 |
| Gutiérrez-Larraya, F | 1 |
| Jabón, A | 1 |
| Beaufort-Krol, GC | 1 |
| Bink-Boelkens, MT | 1 |
| Libersa, C | 1 |
| Caron, J | 1 |
| Broly, F | 1 |
| Lacroix, D | 1 |
| Lhermitte, M | 1 |
| Millar, RN | 1 |
| Lawrenson, JB | 1 |
| Milne, DA | 1 |
| Goedel-Meinen, L | 1 |
| van Hemel, NM | 1 |
| Kingma, JH | 1 |
| Defauw, JJ | 1 |
| Hoogteijling-van Dusseldorp, E | 1 |
| Kelder, JC | 1 |
| Beukema, WP | 1 |
| Vermeulen, FE | 1 |
| Stevens, SK | 1 |
| Haffajee, CI | 1 |
| Naccarelli, GV | 1 |
| Schwartz, KM | 1 |
| Luceri, RM | 1 |
| Packer, DL | 1 |
| Rubin, AM | 1 |
| Kowey, PR | 1 |
| Gillis, AM | 1 |
| Wyse, DG | 1 |
| Mitchell, LB | 1 |
| Duff, HJ | 1 |
| Botto, GL | 1 |
| Bonini, W | 1 |
| Broffoni, T | 1 |
| Molteni, S | 1 |
| Lombardi, R | 1 |
| Alfieri, G | 1 |
| Barone, P | 1 |
| Bernasconi, G | 1 |
| Ferrari, G | 1 |
| Oliveira, M | 1 |
| da Silva, N | 1 |
| Antunes, E | 1 |
| Pinto, E | 1 |
| Cotrim, C | 1 |
| Pitta, L | 1 |
| Cacela, D | 1 |
| Gracias, R | 1 |
| Antunes, AM | 1 |
| O'Rourke, DJ | 1 |
| Palac, RT | 1 |
| Holzberger, PT | 1 |
| Gerling, BR | 1 |
| Greenberg, ML | 1 |
| Gao, E | 1 |
| Yang, C | 1 |
| Li, H | 1 |
| Duan, Y | 1 |
| Zhou, Y | 1 |
| Mastropasqua, F | 1 |
| Totaro, P | 1 |
| Massari, F | 1 |
| Pitzalis, MV | 1 |
| Rizzon, P | 1 |
| Pinter, A | 1 |
| Dorian, P | 1 |
| Bauer, A | 1 |
| Schnabel, PA | 1 |
| Schreiner, KD | 1 |
| Becker, R | 1 |
| Voss, F | 1 |
| Kraft, P | 1 |
| Senges, J | 1 |
| Licka, M | 1 |
| Kübler, W | 1 |
| Schoels, W | 1 |
| Takanaka, C | 1 |
| Nonokawa, M | 1 |
| Machii, T | 1 |
| Lee, S | 1 |
| Kato, H | 1 |
| Haruna, M | 1 |
| Yabe, S | 1 |
| Lombardi, F | 2 |
| Torzillo, D | 2 |
| Sandrone, G | 2 |
| Dalla Vecchia, L | 2 |
| Cappiello, E | 2 |
| Finocchiaro, ML | 1 |
| Bernasconi, R | 1 |
| Herms, J | 1 |
| Schneider, M | 1 |
4 reviews available for propafenone and Tachycardia, Ventricular
| Article | Year |
|---|---|
Flecainide in clinical practice.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Flecainide; Humans; Pregnancy; Propafeno | 2023 |
[Tachycardias: considerations in childhood in the 90s].
Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp | 1993 |
[Guided anti-arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle].
Topics: Adult; Anti-Arrhythmia Agents; Biopsy; Cardiac Pacing, Artificial; Cardiomyopathies; Endocardium; Fe | 1997 |
Intravenous antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Humans; Infusions, Intravenous; Procainamid | 2001 |
12 trials available for propafenone and Tachycardia, Ventricular
| Article | Year |
|---|---|
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bundle-Branch Block; Cardiac Pacing, Artificial; Defibri | 1993 |
Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Hea | 1994 |
Preliminary results of the Cardiac Arrest Study Hamburg (CASH). CASH Investigators.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable | 1993 |
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Sot | 1996 |
Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillators, Impl | 1996 |
Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary?
Topics: Administration, Oral; Age Factors; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Function; Atr | 1996 |
Preliminary study of the effects of metoprolol and propafenone on ventricular arrhythmia with positive ventricular late potential.
Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Metoprolol; Middle Aged; P | 1997 |
[Double-blind randomized placebo-controlled study of the effects of slow release and immediate release forms of propafenone in patients ventricular extrasystole symptoms].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Do | 1998 |
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].
Topics: Adult; Aged; Amiodarone; Death, Sudden, Cardiac; Defibrillators, Implantable; Electrocardiography, A | 1992 |
27 other studies available for propafenone and Tachycardia, Ventricular
| Article | Year |
|---|---|
Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Car | 2022 |
The Wrong Drug That Led to the Right Diagnosis.
Topics: Action Potentials; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; D | 2019 |
Ventricular Tachycardia Induced by Propafenone Intoxication in a Pediatric Patient.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Child, Preschool; Electrocardiography; Humans; | 2019 |
A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Topics: Amiodarone; Anti-Arrhythmia Agents; Child; Death, Sudden, Cardiac; Delayed Diagnosis; Electrocardiog | 2018 |
Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Echocardiography; Electrocardiography; Female; He | 2015 |
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children.
Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr | 2017 |
[Life-threatening ventricular arrhythmia during simultaneous administration of propafenone and sotatol].
Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Humans; Male; Middle Aged; P | 2009 |
A case of myotonic dystrophy presenting with ventricular tachycardia and atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Defibrillators, Implantable | 2009 |
Brugada-like phenomenon, induced by intravenous propafenone, in a patient with idiopathic fascicular ventricular tachycardia.
Topics: Administration, Intravenous; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Heart Co | 2013 |
Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Calsequestrin; Defi | 2011 |
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
Topics: Animals; Anti-Arrhythmia Agents; Calcium; Calcium Signaling; Calsequestrin; Cell Membrane Permeabili | 2011 |
Chronic cough and tachycardia-induced cardiomyopathy in a patient with idiopathic frequent, monomorphic premature ventricular contractions.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chronic Disease; Cough; Female; Humans; Propafenone; | 2013 |
Ventricular tachycardia as a presenting symptom in a child with thrombotic thrombocytopenic purpura.
Topics: Adolescent; Anti-Arrhythmia Agents; Diagnosis, Differential; Electrocardiography; Female; Humans; Me | 2004 |
Monomorphic and propafenone-induced polymorphic ventricular tachycardia in Brugada syndrome: a case report.
Topics: Adult; Ajmaline; Anti-Arrhythmia Agents; Brugada Syndrome; Bundle-Branch Block; Defibrillators, Impl | 2006 |
Clinical experience with propafenone for cardiac arrhythmias in the young.
Topics: Administration, Oral; Adolescent; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature | 1994 |
[The efficacy and safety of intravenous propafenone in the acute treatment of spontaneous sustained ventricular tachycardia].
Topics: Acute Disease; Aged; Chi-Square Distribution; Drug Evaluation; Electrocardiography; Female; Humans; | 1994 |
Frequency-dependent effects of propafenone decrease with duration of ventricular tachycardia in isolated guinea pig hearts.
Topics: Action Potentials; Animals; Electrocardiography; Female; Guinea Pigs; Heart Conduction System; In Vi | 1994 |
Oral propafenone as treatment for incessant supraventricular and ventricular tachycardia in children.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 1993 |
Interaction of propafenone and mexiletine.
Topics: Drug Interactions; Drug Therapy, Combination; Humans; Mexiletine; Propafenone; Tachycardia, Ventricu | 1993 |
Normal left ventricular function does not protect against propafenone-induced incessant ventricular tachycardia.
Topics: Adult; Electrocardiography; Humans; Male; Propafenone; Tachycardia, Ventricular; Ventricular Functio | 1993 |
[Syncope in Lown IVb ventricular arrhythmias and mitral valve prolapse].
Topics: Adult; Electrocardiography, Ambulatory; Humans; Male; Mitral Valve Prolapse; Propafenone; Syncope; T | 1993 |
Propafenone pharmacokinetics and pharmacodynamics in patients with sustained ventricular tachycardia.
Topics: Aged; Anti-Arrhythmia Agents; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardium; Propafe | 1996 |
Propafenone-induced drug fever in the absence of agranulocytosis.
Topics: Agranulocytosis; Anti-Arrhythmia Agents; Diagnosis, Differential; Fever; Humans; Leukocyte Count; Ma | 1997 |
Effects of propafenone on anisotropic conduction properties within the three-dimensional structure of the canine ventricular wall.
Topics: Animals; Anisotropy; Anti-Arrhythmia Agents; Dogs; Heart; Heart Ventricles; Membrane Potentials; Myo | 2001 |
Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; | 1992 |
Autonomic effects of antiarrhythmic drugs and their importance.
Topics: Adult; Autonomic Nervous System; Cardiac Complexes, Premature; Electrocardiography; Female; Flecaini | 1992 |
Beta-blocking effect of propafenone based on spectral analysis of heart rate variability.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Heart Rate; Humans; Posture; Propafenone; Receptor | 1992 |